Protective effect of adenosine triphosphate against sunitinib-related skin damage in rats

ArticleAçık Erişim

Özet

Cutaneous side effects associated with sunitinib use are a major problem in patients receiving cancer treatment. The aim of this study was to investigate the protective effect of adenosine triphosphate (ATP) against possible skin damage resulting from sunitinib use in rats. Thirty Albino Winstar rats were divided into the following three groups: healthy controls (HCs, n = 10), sunitinib (SUN, n = 10), and sunitinib + ATP (SAT, n = 10). ATP was injected intraperitoneally at a dose of 2 mg/kg. One hour subsequent to the administration of ATP and 0.9% NaCl, the SAT and SUN groups were orally administered a dose of 25 mg/kg sunitinib to the stomach. Macroscopic evaluation of the skin indicated lower levels of skin damage in the SAT group than in the SUN group. As an indicator of oxidative stress, malondialdehyde (MDA), total oxidant status (TOS), and oxidative stress index (OSI) levels were significantly higher in the SUN group than in the HC group, while total glutathione (tGSH) and total antioxidant status (TAS) levels were significantly lower. However, MDA, TOS, and OSI levels were significantly lower in the SAT group than in the SUN group, while tGSH and TAS levels were significantly higher. Histopathological examination revealed keratin plugs with edema, vasopathology, and inflammatory cell infiltration in the SUN group. The SAT group showed less necrotic epithelium, keratin plugs, edema, and vasopathology than the SUN group. ATP can be effective in preventing skin damage caused by sunitinib use by reducing oxidative stress. © The Author(s) 2020.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/13476Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1177/0960327120940365Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorYıldırım, N.
dc.contributor.authorKaratas, A.
dc.contributor.authorCengiz, M.
dc.contributor.authorOnalan, E.
dc.contributor.authorYazıcı, G.N.
dc.contributor.authorSunar, M.
dc.contributor.authorMammadov, R.
dc.contributor.authorCoban, A.
dc.contributor.authorSuleyman, H.
dc.date.accessioned2026-10-18T20:28:18.796153601Z
dc.date.available2026-10-18T20:28:18.796153601Z
dc.date.issued2020
dc.description.abstractCutaneous side effects associated with sunitinib use are a major problem in patients receiving cancer treatment. The aim of this study was to investigate the protective effect of adenosine triphosphate (ATP) against possible skin damage resulting from sunitinib use in rats. Thirty Albino Winstar rats were divided into the following three groups: healthy controls (HCs, n = 10), sunitinib (SUN, n = 10), and sunitinib + ATP (SAT, n = 10). ATP was injected intraperitoneally at a dose of 2 mg/kg. One hour subsequent to the administration of ATP and 0.9% NaCl, the SAT and SUN groups were orally administered a dose of 25 mg/kg sunitinib to the stomach. Macroscopic evaluation of the skin indicated lower levels of skin damage in the SAT group than in the SUN group. As an indicator of oxidative stress, malondialdehyde (MDA), total oxidant status (TOS), and oxidative stress index (OSI) levels were significantly higher in the SUN group than in the HC group, while total glutathione (tGSH) and total antioxidant status (TAS) levels were significantly lower. However, MDA, TOS, and OSI levels were significantly lower in the SAT group than in the SUN group, while tGSH and TAS levels were significantly higher. Histopathological examination revealed keratin plugs with edema, vasopathology, and inflammatory cell infiltration in the SUN group. The SAT group showed less necrotic epithelium, keratin plugs, edema, and vasopathology than the SUN group. ATP can be effective in preventing skin damage caused by sunitinib use by reducing oxidative stress. © The Author(s) 2020.
dc.identifier.doi10.1177/0960327120940365
dc.identifier.eissn1477-0903
dc.identifier.endpage1746
dc.identifier.issn0960-3271
dc.identifier.issue12
dc.identifier.pmid32677474
dc.identifier.scopus2-s2.0-85088103846
dc.identifier.startpage1737
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/13476
dc.identifier.volume39
dc.identifier.wosWOS:000549950500001
dc.language.isoen
dc.publisherSAGE Publications Ltd
dc.relation.ispartofHuman and Experimental Toxicology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectadenosine triphosphate
dc.subjectcutaneous side effects
dc.subjectoxidative stress
dc.subjectprotective effect
dc.subjectSunitinib
dc.subjectAnimals
dc.subjectAntineoplastic Agents
dc.subjectGlutathione
dc.subjectMale
dc.subjectMalondialdehyde
dc.subjectProtective Agents
dc.subjectRats, Wistar
dc.subjectSkin
dc.subjectSkin Diseases
dc.subjectkeratin
dc.subjectmalonaldehyde
dc.subjectantineoplastic agent
dc.subjectprotective agent
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectanimal tissue
dc.subjectantioxidant activity
dc.subjectArticle
dc.subjectcell infiltration
dc.subjectcontrolled study
dc.subjectdrug effect
dc.subjectedema
dc.subjecthistopathology
dc.subjectinflammatory cell
dc.subjectmacroscopy
dc.titleProtective effect of adenosine triphosphate against sunitinib-related skin damage in rats
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus8
rdl.citation.wos9
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)